Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

DARK SECRETS: Argx | Vintage Vibes

ARGX Stock Sinks as Argenx Scraps Late-Stage Trial

Argenx shares sink as the company discontinues a Phase 3 trial of Vyvgart in Sjögren’s disease. Is the selloff an opportunity for long-term investors?

Barchart · 14h ago

UBS Just Upgraded Argenx Stock. Here's Why.

Argenx shares rally as UBS issues a bullish note. Here’s how high its analyst expects ARGX stock to fly in 2026.

Barchart · Aug 26

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal

Argenx SE (NASDAQ:ARGX) stock jumped about 12% in Monday’s premarket trading after the company reported positive topline results from its Phase 3 ALKIVIA study.

Benzinga · Aug 17

From analysis to the latest developments in health,
read the most diverse news in one place.

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited notable trading activity ahead of the deal, suggesting possible insider knowledge influencing price action. This case...

Barchart · Jul 30

argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference

argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.

MarketBeat · Jun 5

3 Healthcare Pathbreakers With Long-Term Tailwinds

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

MarketBeat · Sep 1, 2025

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Argenx SE (NASDAQ:ARGX) stock is trading higher on continued upward momentum after the company released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga · Aug 26, 2025

Read news from The Economist, FT, and more,
with one subscription

Argenx Targets FDA Label Expansion After Vyvgart Trial Success

Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab).

Benzinga · Aug 25, 2025

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Benzinga · May 24, 2022

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Argenx SE's (NASDAQ:ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated. A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo…

Benzinga · May 5, 2022

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has

Benzinga · Mar 22, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,980 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.